{"id":62195,"date":"2025-11-13T04:03:21","date_gmt":"2025-11-13T03:03:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/niagen-bioscience-announces-results-from-first-ever-randomized-controlled-trial-exploring-niagen-patented-nicotinamide-riboside-nr-supplementation-in-long-covid\/"},"modified":"2025-11-13T04:03:21","modified_gmt":"2025-11-13T03:03:21","slug":"niagen-bioscience-announces-results-from-first-ever-randomized-controlled-trial-exploring-niagen-patented-nicotinamide-riboside-nr-supplementation-in-long-covid","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/niagen-bioscience-announces-results-from-first-ever-randomized-controlled-trial-exploring-niagen-patented-nicotinamide-riboside-nr-supplementation-in-long-covid\/","title":{"rendered":"Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID"},"content":{"rendered":"
\n

\nFindings show a significant increase in NAD+ levels and within-group benefits in fatigue, depression, and sleep quality<\/i><\/p>\n

LOS ANGELES–(BUSINESS WIRE)–$NAGE<\/a> #Biotech<\/a>—Niagen Bioscience, Inc.<\/a> (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today shared promising results from the first-of-its-kind clinical trial published today in The Lancet<\/i> peer-reviewed journal eClinicalMedicine<\/a><\/i> <\/i>demonstrating that daily supplementation with Niagen\u00ae<\/sup>, Niagen Bioscience\u2019s patented nicotinamide riboside (NR) ingredient, significantly increased NAD+ levels and improved executive functioning, fatigue, depression, and sleep quality, when compared to their baseline levels, in some individuals with long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC).<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe 58 participant, randomized, double-blind, placebo-controlled study was led by Edmarie Guzm\u00e1n-V\u00e9lez, PhD, formerly an Assistant Professor in the Department of Psychiatry and the McCance Center for Brain Health at Massachusetts General Hospital, and now Assistant Professor in the Department of Neurology at the Robert Wood Johnson Medical School, and the Center for Health Aging Research (CHAR) at the Institute for Health, Rutgers University.<\/p>\n

\n\u201cThese findings demonstrate that ten weeks of Niagen NR supplementation increased NAD+ levels and improved long COVID symptoms of fatigue, sleep quality, and depression, compared to symptoms before treatment,\u201d said Rob Fried, Chief Executive Officer of Niagen Bioscience. \u201cAs part of our mission to advance the science of cellular health, we are pleased to see Niagen NR used in research exploring the lasting impact of COVID-19 and look forward to future studies that further our understanding of NAD+ augmentation in recovery and resilience.\u201d<\/p>\n

\nLong COVID continues to affect a significant number of individuals around the globe, with no proven treatments available. According to the U.S. Centers for Disease Control and Prevention<\/a>, between August and September 2024, 5.3% of adults in the U.S. reported that they are currently experiencing long COVID.<\/p>\n

\n\u201cOur goal with this study was to understand whether increasing NAD+ levels with NR could improve cognitive performance primarily, but also other common symptoms in individuals with long COVID,\u201d said Dr. Guzm\u00e1n-V\u00e9lez. \u201cWe saw encouraging within-group improvements in fatigue, sleep, and mood, although we did not observe statistically significant differences between people taking NR and those taking a placebo. These findings suggest that restoring NAD+ remains a promising avenue for recovery and advancing our understanding of how to help individuals affected by long COVID. More research is needed to confirm and expand on these findings.\u201d<\/p>\n

\nThe Connection Between NAD+ & Long COVID<\/b><\/p>\n

\nA multi-system disorder, long COVID symptoms persist months or years after infection, including common fatigue, breathlessness, cognitive impairment or \u201cbrain fog\u201d (attention, memory, sleep), muscle aches, depression, and anxiety (Taher et al., 2025<\/a>, Soriano et al., 2022<\/a>, Ely et al., 2024<\/a>, Taquet et al., 2022<\/a>, Davis et al., 2021<\/a>). Emerging evidence suggests that interacting mechanisms underlie long COVID, including immune dysregulation, mitochondrial dysfunction, oxidative stress, disrupted cellular energy metabolism, and depletion of NAD+, a molecule crucial for cellular energy and repair (Block et al., 2022<\/a>).<\/p>\n

\n\u201cLong COVID presents with a wide range of symptoms because coronaviruses disturb NAD+ and thereby disturb multiple organ systems,\u201d commented Charles Brenner, PhD, Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism at City of Hope, Chief Scientific Advisor to Niagen Bioscience, and study co-author. \u201cWhat is encouraging is that despite variability among patients, we observed consistent signals of improvement with elevation of NAD+ levels. This suggests that restoring the NAD+ system can restore multiple biological pathways implicated in long COVID \u2014 including mitochondrial function, inflammation, and cellular repair. It is a compelling indication that NAD+ biology can be effectively targeted in conditions of metabolic stress such as long COVID.\u201d<\/p>\n

\nStudy Overview<\/b><\/p>\n

\nThis 24-week, randomized, double-blind, placebo-controlled, parallel group study analyzed the effects of elevating NAD+ with Niagen NR supplementation on cognitive and symptomatic recovery in individuals with long COVID.<\/p>\n

\nA total of 58 non-hospitalized adults (mean age, 45.1 years) with persistent symptoms following COVID-19 infection were randomized to receive either Niagen NR (2,000 mg\/day) for 20 weeks or placebo for 10 weeks, followed by Niagen NR for an additional 10 weeks. The study included a two-week placebo lead-in period and a two-week follow-up period.<\/p>\n

\nThe primary endpoint analyzed the change in cognitive performance, measured using validated scales and tests, including the Everyday Cognition (ECog), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and Trail Making Test-B (TMT-B). Secondary endpoints were assessed using standardized scales to evaluate fatigue, mood, and sleep quality (FSS, BDI, BAI, and PSQI).<\/p>\n

\nStudy Highlights<\/b><\/p>\n